COVID-19

NCT: Safety, Tolerability, and Pharmacokinetics of SAB-301 in Healthy Adults

NCT:NCT02788188

Link:NIH Clinical Center Detailed Web Page

Background:

Middle East Respiratory Syndrome (MERS) is a newly discovered contagious and sometimes fatal respiratory virus. People often get MERS through close contact with an infected person. Scientists are worried that MERS may spread and cause more infections. There are no vaccines or treatments for MERS right now. Researchers think a new therapy called SAB-301 may be able to help. Antibodies are proteins the body makes to attack viruses. SAB-301 is made of antibodies made in cows to fight MERS. The antibodies are collected from plasma, the liquid part of cow blood. (Source: https://clinicaltrials.gov/ct2/show/NCT02788188)

Other study identifiers:160119, 16-I-0119

Start date:May 28, 2016

Completion date:April 30, 2018 (Actual)

Primary completion date:April 10, 2018 (Actual)

Study first submitted:May 28, 2016

Last update posted:June 12, 2018

Locations:United States

Sponsor:National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators:Naval Medical Research Center, SAB Biotherapeutics, Inc

Keywords:First in Human, Middle East Respiratory Syndrome (MERS), Tc Bovine-Derived, Transchromosomic Cattle

Enrollment:38

READ MORE …

SOURCE: https://clinicaltrials.gov/ct2/show/NCT02788188